Hypertensive crisis secondary to phenylpropanolamine interacting with triple-drug therapy for HIV prophylaxis

      Major advances in therapy of the human immunodeficiency virus (HIV) have occurred during the last several years, with many new and efficacious medications becoming available. Regulatory policies regarding pre–market testing of anti-HIV drugs are more lenient than for other agents, and many newer drugs have been accelerated through the trial process, as their proposed benefits of early availability outweigh the risks of unusual and unpredictable adverse reactions. Hence, many adverse reactions are reported in postmarketing surveillance, leading to modifications in the recommendations and precautions regarding the use of these agents. We report an unusual drug interaction that may have wide implications for prescribers and the recipients of such medications.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Benet L
        • Oie S
        • Schwartz J.Clemastine
        Goodman L Gilman A Goodman and Gilman’s Pharmacological Basis of Therapeutics. McGraw-Hill, New York1996
        • Lake C.R
        • Gallant S
        • Mason E
        • Miller P
        Adverse drug effects attributed to phenylpropanolamine.
        Am J Med. 1990; 89: 195-208
        • Conant M
        • Okabe M
        • Slaton A
        • et al.
        Stavudine (d4T) therapy.
        (Abstract.) Int Conf AIDS. 1994; 10: 7
        • Adler M.H
        • Anderson R.E
        • Rutkiewicz V
        • et al.
        Clinical course of long term therapy with stavudine (d4T).
        (Abstract.) Intersci Conf Antimicrob Agents Chemother. 1994; 218